Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents
- 440 Downloads
Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. For this reason, there is a great deal of interest in determining how therapies commonly used to treat patients with diabetes impact cardiovascular outcomes. Results from recently completed cardiovascular outcomes trials of diabetes agents from several medication classes are leading to a sea change in how we think about diabetes treatment. The primary focus of this paper is to review recently completed and ongoing diabetes medication cardiovascular outcomes trials. We also review cardiovascular outcome evidence for other classes of medications commonly used in patients with diabetes (i.e., aspirin, anti-hypertensive agents, lipid-lowering agents, and weight loss medications).
Compliance with Ethical Standards
No external funds were used in the preparation of this manuscript.
Conflicts of interest
David R. Saxon has no disclosures to report. Neda Rasouli has served as the site principal investigator for medication trials for Novo Nordisk, Bristol-Meyers Squibb, Intarcia Therapeutics, Inc., Calibra Medical, GlaxoSmithKline, Amylin, Boehringer Ingelheim, Ionis Pharmaceuticals, and Regeneron. Robert H. Eckel has served as a consultant for Novo Nordisk and Merck.
- 5.Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [internet]. 2008. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 6 July 2017.
- 13.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.Google Scholar
- 14.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.Google Scholar
- 18.Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887–97.CrossRefPubMedGoogle Scholar
- 21.US Food and Drug Administration. Rosiglitazone-containing diabetes medicines: drug safety communication—FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) [internet]. 2015. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm477601.htm. Accessed 7 July 2017.
- 22.Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet Lond Engl. 2005;366:1279–89.CrossRefGoogle Scholar
- 30.Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.Google Scholar
- 31.Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk [internet]. 2017. https://www.astrazeneca.com/media-centre/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-23052017.html. Accessed 7 July 2017.
- 32.Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes [internet]. 2016. https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html. Accessed 7 July 2017.
- 36.US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [internet]. 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed 7 July 2017.
- 40.Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877–86.CrossRefPubMedGoogle Scholar
- 42.Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.CrossRefPubMedGoogle Scholar
- 44.ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA. 1992;268:1292–1300.Google Scholar
- 46.Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.ASCEND: a study of cardiovascular events iN Diabetes [internet]. 2015. https://clinicaltrials.gov/ct2/show/NCT00135226. Accessed 7 July 2017.
- 52.A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE) [internet]. 2017. https://clinicaltrials.gov/ct2/show/NCT00501059. Accessed 7 July 2017.
- 53.De Berardis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36:555–64.Google Scholar
- 55.Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45.CrossRefPubMedGoogle Scholar
- 63.Lally S, Tan CY, Owens D, et al. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006;49:1008–16.CrossRefPubMedGoogle Scholar
- 69.Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10—should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44.CrossRefPubMedGoogle Scholar
- 71.Osborne S. Orexigen pulls the plug on post-marketing cardiovascular trial [internet]. 2016. http://seekingalpha.com/article/3965636-orexigen-pulls-plug-post-marketing-cardiovascular-trial. Accessed 7 July 2017.
- 72.A study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors [internet]. 2017. https://www.clinicaltrials.gov/show/NCT02019264. Accessed 7 July 2017.
- 73.Vivus announces operational update [internet]. 2017. http://ir.vivus.com/releasedetail.cfm?ReleaseID=904060. Accessed 7 July 2017.